SAN FRANCISCO, CA, Pendulum Therapeutics, a biotech company improving health through products targeting the microbiome, today announced a $54 million investment.
The round was led by Meritech Capital with participation from existing investors including Sequoia Capital, True Ventures and Khosla Ventures. This Series C round nearly doubled the entirety of Pendulum's previous raises and brings the total venture capital raised to $111 million.
Pendulum Therapeutics believes therapies developed using evidence-based microbiome science and DNA sequencing can help heal the body from within. Armed with 13 patents and 42 pending, the company introduced its flagship product Pendulum Glucose Control, a medical probiotic, in 2020 and demonstrated its efficacy in lowering blood sugar spikes and reducing A1C in a published clinical trial. Founded in 2013 by a diverse team of scientists with deep microbiology, biochemistry, computational, and clinical expertise, Pendulum has raised $111 million to date from Meritech Capital, Sequoia Capital, True Ventures, Khosla Ventures, AME Cloud Ventures and Mayo Clinic among others. Pendulum Therapeutics is headquartered in San Francisco.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about